← Leaderboards
Yanguang Cao
Univ Of North Carolina Chapel Hill
$3,523,520
Attributed
$3,523,520
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $634.2K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,884,949 · 2
FDA$638,571 · 1
By mechanism
R35$2,884,949 · 2
U01$638,571 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Amanda E Nelson$9,806,242
- Gianpietro Dotti$17,018,250
- Kathleen M Caron$16,068,293
- Beverly H Koller$30,354,187
- Bruce A Cairns$5,721,017
Others in their field
Top investigators on “Binding”
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Barton F Haynes · Duke University$280,359,422
- David Heimbrook · Leidos Biomedical Research, Inc.$116,636,515
- Michael P Snyder · Yale University$97,195,243
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
Research focus
BindingCellsEnvironmentTissuesMolecular ImagingAntibodiesTherapeutic AntibodiesSuccessDrug KineticsAntibody TherapyIn VivoPhysiologyImmunological StatusIntercellular FluidBloodDrug SensitivityInfiltrationFda ApprovedDoseAutoimmune DiseasesFaceExposure ToImmune SystemAntigens
Grant awards (14)
Quantitative Systems Pharmacology of Antibody Therapeutics across Diverse Biological Contexts$392,134
R35 · FY2025 · GM · contact PI
Quantitative Systems Pharmacology of Antibody Therapeutics across Diverse Biological Contexts$392,134
R35 · FY2024 · GM · contact PI
Optimizing antibody-based therapy through a system platform of pharmacokinetics-pharmacodynamics-immunodynamics$370,335
R35 · FY2020 · GM · contact PI
Optimizing antibody-based therapy through a system platform of pharmacokinetics-pharmacodynamics-immunodynamics$371,890
R35 · FY2019 · GM · contact PI
Optimizing antibody-based therapy through a system platform of pharmacokinetics-pharmacodynamics-immunodynamics$462,763
R35 · FY2018 · GM · contact PI
Optimizing antibody-based therapy through a system platform of pharmacokinetics-pharmacodynamics-immunodynamics$104,935
R35 · FY2018 · GM · contact PI
Optimizing antibody-based therapy through a system platform of pharmacokinetics-pharmacodynamics-immunodynamics$47,539
R35 · FY2018 · GM · contact PI
Optimizing antibody-based therapy through a system platform of pharmacokinetics-pharmacodynamics-immunodynamics$373,041
R35 · FY2017 · GM · contact PI
Optimizing antibody-based therapy through a system platform of pharmacokinetics-pharmacodynamics-immunodynamics$370,178
R35 · FY2016 · GM · contact PI
Physiologically Based Pharmacokinetic Model for Drugs Encapsulated into Liposomes$168,667
U01 · FY2016 · FD · contact PI
Physiologically Based Pharmacokinetic Model for Drugs Encapsulated into Liposomes$95,397
U01 · FY2016 · FD · contact PI
Physiologically Based Pharmacokinetic Model for Drugs Encapsulated into Liposomes$175,978
U01 · FY2015 · FD · contact PI
Physiologically Based Pharmacokinetic Model for Drugs Encapsulated into Liposomes$133,563
U01 · FY2014 · FD · contact PI
Physiologically Based Pharmacokinetic Model for Drugs Encapsulated into Liposomes$64,966
U01 · FY2014 · FD · contact PI